A class action lawsuit has been initiated against Vistagen Therapeutics, Inc., alleging the biopharmaceutical company made materially false and misleading statements regarding its fasedienol drug candidate and related clinical trial data. The litigation, filed by Bronstein, Gewirtz & Grossman LLC, targets investors who purchased company securities during a 20-month period spanning April 1, 2024, through December 16, 2025.
The complaint centers on alleged misrepresentations concerning the PALISADE-3 clinical trial, a key development program for Vistagen's pipeline. According to the lawsuit, investors were not properly informed about material information affecting the trial's progress and outcomes, potentially causing financial losses for those who held the company's securities during the relevant timeframe.
Investors who purchased Vistagen securities during the specified period and believe they sustained losses as a result of the alleged misconduct are encouraged to contact counsel. The deadline for investors to be named as lead plaintiffs in the action is March 16, 2026. The case remains ongoing, and no determination of liability has been made at this stage.